Carregant...
BCL-2 inhibition – stemming the tide of myeloid malignancies
Leukemia stem cells (LSC) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. (Lagadinou et al., 2013) and (Goff et al., 2013) find that LSC can be selectively targeted by small molecule antagonists of anti-apoptotic BCL-2 family proteins.
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3705714/ https://ncbi.nlm.nih.gov/pubmed/23472867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.stem.2013.02.006 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|